MiNK Therapeutics: KDJ Golden Cross, Bullish Marubozu Pattern on 15-Minute Chart

According to MiNK Therapeutics' 15-minute chart, the KDJ Golden Cross and Bullish Marubozu at 08/29/2025 09:45 indicate a shift in momentum towards the upside. This suggests that the stock price has the potential to continue increasing, as buyers are in control of the market. Furthermore, the bullish momentum is likely to persist.

Agenus Inc. (Nasdaq: AGEN), a leading immuno-oncology company, has announced an update to its virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m. ET. The webcast, now available in a new virtual format, will provide an engaging experience for attendees and cover key strategic and financial updates. The session will feature presentations from Agenus' leadership team and experts in the field.

The webcast will delve into several significant topics, including:

- Zydus Partnership Momentum: Updates on the progress and execution of the partnership between Agenus and Zydus, focusing on the potential benefits and advancements in colorectal cancer (CRC) studies.
- Clinical Updates: Recent updates on the BOT/BAL clinical programs, including the Phase 3 BATTMAN study in metastatic CRC.
- MiNK Therapeutics Spotlight: Highlighting the significant stakeholder relationship with MiNK Therapeutics and the potential of its pipeline of iNKT cell therapies.
- Upcoming Milestones: Overview of the company's upcoming milestones across its portfolio.

Speakers to the webcast will include:

- Garo H. Armen, PhD: Founder, Chairman, and CEO of Agenus.
- Richard M. Goldberg, MD: Chief Development Officer of Agenus.
- Nicholas C. DeVito, MD: Assistant Professor of Medical Oncology at Duke University.
- Chris O'Callaghan, DVM, MSc, PhD: Senior Investigator at Canadian Cancer Trials Group (CCTG).
- Jen Buell, PhD: Chief Executive Officer, MiNK Therapeutics.

The webcast will conclude with a live Q&A session, allowing attendees to engage with the speakers and gain deeper insights into Agenus' strategic direction and clinical pipeline.

Implications for Investors:

The webcast provides an opportunity for investors to gain a comprehensive understanding of Agenus' strategic initiatives and clinical progress. The company's robust pipeline of immunological agents and its partnerships with leading organizations in the field position Agenus as a key player in the immuno-oncology space. The updates on the BOT/BAL clinical programs and the MiNK Therapeutics spotlight are particularly noteworthy, as they highlight Agenus' commitment to innovative therapies and its potential for significant growth.

MiNK Therapeutics Update:

Separately, MiNK Therapeutics' stock performance has been in focus, with its 15-minute chart triggering a KDJ Golden Cross and Bullish Marubozu at 08/29/2025 09:45 [2]. This suggests a shift in momentum towards the upside, indicating that buyers are in control of the market. The bullish momentum is likely to persist, positioning MiNK for potential investor interest.

References:
[1] https://www.morningstar.com/news/business-wire/20250826512064/update-agenus-aug-27-stakeholder-webcasttransformative-io-updates-botbal-data-battman-preview-zydus-partnership-momentum-and-mink-spotlight
[2] https://www.ainvest.com/news/mink-therapeutics-15min-chart-triggered-kdj-death-cross-bearish-marubozu-signal-2508/